Novel Central Nervous System (CNS)-Targeting Protease Inhibitors for Drug-Resistant HIV Infection and HIV-Associated CNS Complications.

Antimicrob Agents Chemother 2019 07 24;63(7). Epub 2019 Jun 24.

Department of Infectious Diseases, Kumamoto University School of Medicine, Kumamoto, Japan

There is currently no specific therapeutics for the HIV-1-related central nervous system (CNS) complications. Here we report that three newly designed CNS-targeting HIV-1 protease inhibitors (PIs), GRL-083-13, GRL-084-13, and GRL-087-13, which contain a P1-3,5--fluorophenyl or P1--monofluorophenyl ring, and P2--tetrahydrofuran (-THF) or P2-tetrahydropyrano-tetrahydrofuran (-THF), with a sulfonamide isostere, are highly active against wild-type HIV-1 strains and primary clinical isolates (50% effective concentration [EC], 0.0002 to ∼0.003 μM), with minimal cytotoxicity. These CNS-targeting PIs efficiently suppressed the replication of HIV-1 variants (EC, 0.002 to ∼0.047 μM) that had been selected to propagate at high concentrations of conventional HIV-1 PIs. Such CNS-targeting PIs maintained their antiviral activity against HIV-2 as well as multidrug-resistant clinical HIV-1 variants isolated from AIDS patients who no longer responded to existing antiviral regimens after long-term therapy. Long-term drug selection experiments revealed that the emergence of resistant-HIV-1 against these CNS-targeting PIs was substantially delayed. In addition, the CNS-targeting PIs showed the most favorable CNS penetration properties among the tested compounds, including various FDA-approved anti-HIV-1 drugs, as assessed with the blood-brain barrier reconstruction system. Crystallographic analysis demonstrated that the bicyclic rings at the P2 moiety of the CNS-targeting PIs form strong hydrogen-bond interactions with HIV-1 protease (PR) active site. Moreover, both the P1-3,5--fluorophenyl and P1--monofluorophenyl rings sustain greater van der Waals contacts with PR than in the case of darunavir (DRV). The data suggest that the present CNS-targeting PIs have desirable features for treating patients infected with wild-type and/or multidrug-resistant HIV-1 strains and might serve as promising preventive and/or therapeutic candidates for HIV-1-associated neurocognitive disorders (HAND) and other CNS complications.

Download full-text PDF

Source
http://dx.doi.org/10.1128/AAC.00466-19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6591644PMC
July 2019
3 Reads
4.476 Impact Factor

Publication Analysis

Top Keywords

cns-targeting pis
24
cns complications
12
hiv-1 variants
8
protease inhibitors
8
hiv-1 strains
8
cns-targeting
8
pis
8
hiv-1 protease
8
central nervous
8
p1-35--fluorophenyl p1--monofluorophenyl
8
nervous system
8
hiv-1
7
pis delayed
4
resistant-hiv-1 cns-targeting
4
experiments revealed
4
drug selection
4
long-term drug
4
selection experiments
4
delayed addition
4
revealed emergence
4

References

(Supplied by CrossRef)
Strategies in the design of antiviral drugs
De Clercq et al.
Nat Rev Drug Discov 2002
A long-term latent reservoir for HIV-1
Siliciano et al.
J Antimicrob Chemother 2004
HIV-1 dynamics in vivo: implications for therapy
Simon et al.
Nat Rev Microbiol 2003
New patterns of HIV-1 resistance during HAART
Fumero et al.
Clin Microbiol Infect 2003
HIV infection in older patients in the HAART era
Grabar et al.
J Antimicrob Chemother 2006
Immune reconstitution in HIV-infected patients
Hirsch et al.
Clin Infect Dis 2004

Similar Publications